Bonothyrk

The effectiveness of Bonothyrk has been confirmed in clinical studies. It helps restore the functional activity of the parathyroid glands in disorders of various origins, including hyperparathyroidism, osteoporosis, bone demineralisation, urolithiasis and muscle weakness. It also helps in hypoparathyroidism, including hypocalcaemia, muscle cramps and muscle numbness.

Recommended for:

• osteoporosis;
• bone demineralisation;
• urolithiasis;
• muscle weakness due to parathyroid hyperplasia;
• muscle cramps and numbness caused by hypocalcaemia.

Ingredients:

Microcrystalline cellulose (bulking agent); hydroxypropyl methylcellulose (capsule shell), water, carrageenan (thickener), potassium acetate (acidity regulator); peptide complex A‑21 containing amino acids (glutamic acid, aspartic acid, alanine, leucine, valine, isoleucine, proline, serine); calcium salts of fatty acids (anti-caking agent).

The recommended daily dose of 2 or 4 capsules contains 20 or 40 mg of peptide complex A‑21.

Directions for use:

Adults: 1–2 capsules twice a day with meals. Course: 1 month. The course may be repeated after 3–6 months.